← Back to patent-cliff list
Olaptesed Pegol
Tier C — Watch / tradeOlaptesed Pegol
Noxxon Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CXCL12
Indications (approved)：Pancreatic cancer, Glioblastoma, Colorectal cancer, Chronic lymphocytic leukaemia, Multiple myeloma, Haematopoietic stem cell transplantation
Regional status
US
-
EU
Phase II
2012-03-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Olaptesed Pegol?
Approved indications include: Pancreatic cancer, Glioblastoma, Colorectal cancer, Chronic lymphocytic leukaemia, Multiple myeloma, Haematopoietic stem cell transplantation.
When does the Olaptesed Pegol patent expire?
No public expiry year is available for Olaptesed Pegol yet; this page updates once verified.
How do I get a quote for Olaptesed Pegol intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-18